Sequential cis-platinum and VM26 in neuroblastoma: laboratory and clinical (OPEC regimen) studies.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D004357:Drug Synergism; D006801:Humans; D007223:Infant; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D003520:Cyclophosphamide; D013713:Teniposide; D011034:Podophyllotoxin; D002945:Cisplatin